血管新生抑制剂特异性高血压增加了发展大动脉剖析的风险
Kaito Tsujinaka1, Yuki Izawa-Ishizawa2, Koji Miyata3
1Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan; Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|September 18, 2023
概括
血管生成抑制剂,用于癌症治疗,通过破坏内皮细胞和增加内皮蛋白-1表达,增加了大动脉解剖的风险. 这项研究澄清了它们的血管毒性,帮助制定更安全的治疗策略.
科学领域:
- 在瘤学瘤学.
- 血管生物学 血管生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 大动脉解剖是与血管生成抑制剂相关的已知不良事件.
- 这些药物与大动脉剖析之间的确切关系尚不清楚.
- 了解这种联系对于癌症治疗中的患者安全至关重要.
研究的目的:
- 为了研究血管新生抑制剂与大动脉解剖开始之间的关联.
- 阐明这些药物可能增加大动脉解剖风险的机制.
- 通过多方方法评估血管生成抑制剂的血管毒性.
主要方法:
- 使用药理学诱导的易发生大动脉剖析的小鼠模型 (LAB小鼠).
- 用培养的内皮细胞进行了体外研究.
- 在全球不良事件数据库上进行了不成比例分析,并在JMDC数据库上进行了回顾性队列分析.
主要成果:
- 血管生成抑制剂,与其他高血压诱导药物不同,显示出大动脉动脉瘤和剖析的显著风险信号.
- 在实验室小鼠中,苏尼替尼增加了血压和大动脉剖析发生率,同时增加了内甲蛋白-1和内皮细胞损伤标志物.
- 动脉样硬化和脂质失调史,而不是高血压,与血管新生抑制剂使用期间的剖析有关.
结论:
- 血管生成抑制剂通过药物特异性高血压,内皮细胞损伤和增加内皮林-1表达增加了大动脉解剖风险.
- 这些发现提供了关于血管新生抑制剂的血管毒性机制的见解.
- 这项研究对于开发更安全的抗癌疗法和预防高风险患者血管并发症至关重要.
相关概念视频
01:25Antihypertensive Drugs: Direct Renin Inhibitors
677
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
677
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
687
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
687
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
776
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
776
01:26Aneurysm III: Interprofessional Care
9
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
9
01:21Aneurysm II: Clinical Manifestations and Diagnostic Studies
10
Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
10
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
460
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
460